Ayako Hirai1, Kazue Yoneda2, Shohei Shimajiri3, Koji Kuroda1, Takeshi Hanagiri4, Yoshihisa Fujino5, Fumihiro Tanaka1. 1. Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health, Kitakyushu, Japan. 2. Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health, Kitakyushu, Japan. Electronic address: yoneda@med.uoeh-u.ac.jp. 3. Second Department of Pathology and Cell Biology, University of Occupational and Environmental Health, Kitakyushu, Japan. 4. Department of Thoracic Surgery, Shin-Kokura Hospital, Kitakyushu, Japan. 5. Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health, Kitakyushu, Japan.
Abstract
OBJECTIVE: The study objective was to investigate the prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression on tumor cells in early-stage adenocarcinoma of the lung, because both programmed death-ligand 1 and human leukocyte antigen class I molecules play important roles in cancer immunity. METHODS: Ninety-four patients with completely resected pathologic stage I lung adenocarcinoma were retrospectively reviewed. Programmed death-ligand 1 expression on tumor cells was evaluated with immunohistochemistry in correlation with several clinicopathologic and molecular features, including human leukocyte antigen class I expression on tumor cells. RESULTS: Fifteen patients (16.0%) had tumor with positive programmed death-ligand 1 expression (percentage of tumor cells expressing programmed death-ligand 1, ≥5%), and the incidence was significantly higher in poorly differentiated tumors. There was no significant correlation between human leukocyte antigen class I expression and programmed death-ligand 1 expression. Programmed death-ligand 1 positivity was a significant factor to predict a poor survival (5-year survival, 66.7% vs 85.9%; P = .049), which was enhanced in tumors with normal human leukocyte antigen class I expression (P = .029) but was not evident in tumors with reduced human leukocyte antigen class I expression (P = .552). CONCLUSIONS: The prognostic impact of programmed death-ligand 1 expression on tumor cells in early-stage lung adenocarcinoma may be distinct according to concurrent human leukocyte antigen class I expression.
OBJECTIVE: The study objective was to investigate the prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression on tumor cells in early-stage adenocarcinoma of the lung, because both programmed death-ligand 1 and human leukocyte antigen class I molecules play important roles in cancer immunity. METHODS: Ninety-four patients with completely resected pathologic stage I lung adenocarcinoma were retrospectively reviewed. Programmed death-ligand 1 expression on tumor cells was evaluated with immunohistochemistry in correlation with several clinicopathologic and molecular features, including human leukocyte antigen class I expression on tumor cells. RESULTS: Fifteen patients (16.0%) had tumor with positive programmed death-ligand 1 expression (percentage of tumor cells expressing programmed death-ligand 1, ≥5%), and the incidence was significantly higher in poorly differentiated tumors. There was no significant correlation between human leukocyte antigen class I expression and programmed death-ligand 1 expression. Programmed death-ligand 1 positivity was a significant factor to predict a poor survival (5-year survival, 66.7% vs 85.9%; P = .049), which was enhanced in tumors with normal human leukocyte antigen class I expression (P = .029) but was not evident in tumors with reduced human leukocyte antigen class I expression (P = .552). CONCLUSIONS: The prognostic impact of programmed death-ligand 1 expression on tumor cells in early-stage lung adenocarcinoma may be distinct according to concurrent human leukocyte antigen class I expression.
Authors: Minghui Zhang; Guoliang Li; Yanbo Wang; Yan Wang; Shu Zhao; Pu Haihong; Hongli Zhao; Yan Wang Journal: Sci Rep Date: 2017-08-31 Impact factor: 4.379